Plavix, Clopidogrel News

Main Category: Cardiovascular / Cardiology Also Included In: Clinical Trials / Drug Trials Article Date: 20 Nov 2009 Accumetrics, Inc., developer of the VerifyNow System, the first point-of-care method for measuring platelet reactivity, announces that its market-leading VerifyNow P2Y12 Test was one of multiple methods evaluated in the POPular ...

AstraZeneca today announced it has submitted a New Drug Application to the U.S. Food and Drug Administration for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome .

ROCKVILLE,A Md. Patients taking an anticlotting drug should avoid the use of a drug for gastroesophageal reflux disease, the Food and Drug Administration warned Wednesday.

The FDA is updating clopidogrel's label to warn against its concomitant use with the proton-pump inhibitor omeprazole.

How many times have you found yourself at the gym-in a group fitness class, let's say-and you're wondering where went the energy you possessed last night at the club? Why isn't this body conditioning class as high energy as you and your posse cavorting on the dance floor? Of course, if you've ever been in one of fitness guru Heather Cohen's House ...

November 19, 2009 Ticagrelor data presented at the American Heart Association Scientific Sessions Orlando, FL /PRNewswire-FirstCall/ --AstraZeneca today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor ) at the annual American Heart Association Scientific Sessions in Orlando, FL, with ONSET/OFFSET study results ...

The U.S. Food and Drug Administration is warning patients against using the stomach acid reducer Prilosec with the anti-clotting drug Plavix.

FDA notified healthcare professionals of new safety information concerning an interaction between clopidogrel , an anti-clotting medication, and omeprazole , a proton pump inhibitor used to reduce stomach acid.

After years of little progress, three new trials suggest that the latest generation of blood thinners may outperform the old standbys warfarin and clopidogrel .

Federal health officials said Tuesday a popular variety of heartburn medications can interfere with the blood thinner Plavix, a drug taken by millions of Americans to reduce risks of heart attack and stroke.

Patients who are taking clopidogrel should avoid the concomitant use of omeprazole, a proton-pump inhibitor , because the latter drug diminishes the antiplatelet effects of clopidogrel, FDA announced today.

November 15, 2009 AstraZeneca today announced results of a PLATO sub-analysis in the most serious type of Acute Coronary Syndrome patients, those with ST Segment Elevation Myocardial Infarction .

The Food and Drug Administration say the stomach-soothing drug Prilosec lowers the effectiveness of Plavix by half.

" Two large studies confirmed that an investigational, reversible anti-clotting medication failed to show greater effectiveness than clopidogrel or a placebo for patients undergoing a procedure to open blocked coronary arteries, according to researchers at the Duke Clinical Research Institute.

Submitted by admin on 11/15/2009 @ 6:00 AM Companies mentioned in this article: American Heart Association Study highlights: -STEMI patients had fewer cardiac events with a new reversible oral anti-platelet drug compared to standard treatment with an irreversible agent.

People taking the acid reflux drugs Prilosec or Protonix in combination with blood thinners such as Plavix have a higher risk for death after angioplasty than people who don't take the two popular antacids, a new study has found.

While cangrelor did not show superiority to 600 mg clopidogrel given orally for the pre-specified primary endpoint comprising death, MI, or ischemia driven revascularization at 48 hours, full analysis of the CHAMPION program data revealed strong evidence of pharmacological effects, clinical effectiveness and suitable safety in patients undergoing ...

Results from a new study showed patients with type 2 diabetes mellitus who also had coronary artery disease and received a 60 mg loading dose and 10 mg maintenance dose of Effient achieved significantly greater platelet inhibition compared with a 600 mg loading dose and 150 mg maintenance dose of Plavix .

American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis Study highlights: - Used during coronary angioplasty plus stenting, in patients who all received clopidogrel after the procedure, a new reversible blood thinner did ...

Heart attack patients in need of emergency procedures were less likely to suffer further serious cardiovascular events, including deaths, when given AstraZeneca's experimental Brilinta blood clot preventer than those who received used Plavix, according to a study.